NCT00379977

Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age

Open, Primary Vaccination Study to Assess Safety and Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Administered to Healthy Chinese Infants at 3, 4 and 5 Months of Age.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 30 (planned)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 90 Days – 120 Days
• Healthy volunteers: Accepted

Summary

This study will evaluate the safety and reactogenicity of GSK Biologicals' Diphtheria Tetanus acellular Pertussis/Haemophilus influenzae type b vaccine given to Chinese infants at 3, 4 and 5 months of age.

Conditions

• Tetanus
• Haemophilus Influenzae Type b
• Acellular Pertussis
• Diphtheria

Interventions

Type	Name	Description
BIOLOGICAL	diphtheria, tetanus, pertussis & Hib vaccine

Timeline

• Start date: 2006-09-01
• Completion: 2006-12-01
• First posted: 2006-09-25
• Last updated: 2016-10-12

Locations

1 site across 1 country: China